Abstract
Compound KAD22 (5-methoxy-1-methyl-2-{[4-(2-hydroxyphenyl)piperazin-1-yl]methyl}- 1H-indole) was designed as a potential dopamine D2 receptor agonist with antioxidant activity for possible treatment of Parkinson’s disease. The compound was obtained from 5-methoxy-1-methyl-1H-indole- 2-carbaldehyde and 2-(piperazin-1-yl)phenol. KAD22 showed no affinity to dopamine D2 receptor but it is a potent antioxidant. Experimental and computational structural studies (conformational analysis, HOMO and LUMO orbitals, electrostatic potential map, non-covalent interaction plot, spectral properties, ligand-receptor interactions) of KAD22 were performed to address its biological activity.
Keywords: Antioxidant activity, dopamine receptors, indole derivatives, molecular modeling, Parkinson’s disease, structural studies.
Graphical Abstract
[http://dx.doi.org/10.1007/s00702-017-1686-y] [PMID: 28150045]
[http://dx.doi.org/10.1111/j.1468-1331.2005.01202.x] [PMID: 15877774]
[http://dx.doi.org/10.1001/jama.2019.22360] [PMID: 32044947]
[http://dx.doi.org/10.1586/17512433.2014.966812] [PMID: 25318835]
[http://dx.doi.org/10.1002/mds.28064] [PMID: 32347983]
[http://dx.doi.org/10.1016/j.molmed.2012.11.005] [PMID: 23265841]
[http://dx.doi.org/10.1016/S0074-7742(07)82016-2] [PMID: 17678968]
[http://dx.doi.org/10.3390/antiox9010052]
[http://dx.doi.org/10.1016/j.ejmech.2020.112385] [PMID: 32402936]
[http://dx.doi.org/10.2174/0929867324666170724102743] [PMID: 28738770]
[http://dx.doi.org/10.3390/ijms20143380]
[http://dx.doi.org/10.1016/S1043-9471(05)80049-7]
[http://dx.doi.org/10.1002/cmdc.200900398] [PMID: 20077461]
[http://dx.doi.org/10.1016/j.foodchem.2019.02.103] [PMID: 30902314]
[http://dx.doi.org/10.5530/pj.2018.6.189]
[http://dx.doi.org/10.1002/qua.22555]
[http://dx.doi.org/10.3390/molecules17022140] [PMID: 22354191]
[http://dx.doi.org/10.1007/s11224-006-9048-7]
[http://dx.doi.org/10.1021/ja100936w] [PMID: 20394428]
[http://dx.doi.org/10.1039/C4MD00066H]
[http://dx.doi.org/10.1002/mrc.2060] [PMID: 17729232]
[http://dx.doi.org/10.1016/j.ejmech.2014.02.058] [PMID: 24631727]
[http://dx.doi.org/10.1016/j.neuropharm.2006.03.021] [PMID: 16697427]
[http://dx.doi.org/10.1002/cmdc.201500599] [PMID: 26990027]
[http://dx.doi.org/10.1016/j.neuint.2016.03.003] [PMID: 26964765]
[http://dx.doi.org/10.2174/1573406411309030002] [PMID: 22741788]
[http://dx.doi.org/10.1021/ct100641a] [PMID: 21516178]
[http://dx.doi.org/10.1016/0263-7855(96)00018-5] [PMID: 8744570]
[http://dx.doi.org/10.1016/j.molstruc.2015.09.025]
[http://dx.doi.org/10.1016/j.poly.2017.11.003]
[http://dx.doi.org/10.1016/0301-0104(81)85090-2]
[http://dx.doi.org/10.1016/0009-2614(92)85733-Q]
[http://dx.doi.org/10.1016/0009-2614(93)89127-4]
[http://dx.doi.org/10.1063/1.471789]
[http://dx.doi.org/10.1016/j.saa.2013.05.096]
[http://dx.doi.org/10.1080/00958972.2015.1073268]
[http://dx.doi.org/10.1021/jm400923s] [PMID: 24083878]
[http://dx.doi.org/10.1021/jm051256o] [PMID: 17034125]
[http://dx.doi.org/10.1016/j.ejmech.2019.07.050] [PMID: 31357129]
[http://dx.doi.org/10.3390/biom10020349]